Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL391560 | 0.81 | NPSR1 (0.33) | NPSR1 | |
| SCHEMBL5455757 | 0.72 | NPSR1 (0.40) | NPSR1 | |
| SCHEMBL11210558 | 0.70 | NPSR1 (0.44) | NPSR1 | |
| SCHEMBL11221244 | 0.69 | NPSR1 (0.31) | NPSR1 | |
| Hydrochloric Acid SCHEMBL11211543 | 0.68 | NPSR1 (0.43) | NPSR1 | |
| SCHEMBL27280313 | 0.64 | NPSR1 (0.37) | NPSR1 | |
| SCHEMBL252416 | 0.63 | — | — | |
| SCHEMBL7604115 | 0.63 | NPSR1 (0.35) | NPSR1 | |
| SCHEMBL9558520 | 0.62 | — | — | |
| SCHEMBL27843476 | 0.62 | LTB4R (0.41) | PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030229076-A1 | Substituted imidazoles as selective modulators of bradykinin B2 receptors | RACHWAL STANISLAW (US) | 2003-12-11 | — | — | US | disclosed |
| US-6509366-B2 | Substituted imidazoles as selective modulators of Bradykinin B2 receptors | NEUROGEN CORPORATION | 2003-01-21 | — | — | US | disclosed |
| US-20020115693-A1 | Substituted imidazoles as selective modulators of bradykinin B2 receptors | NEUROGEN CORPORATION | 2002-08-22 | — | — | US | disclosed |
| WO-2001056995-A1 | SUBSTITUTED IMIDAZOLES AS SELECTIVE MODULATORS OF BRADYKININ B2 RECEPTORS | NUEROGEN CORPORATION (US) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229076-A1 | Substituted imidazoles as selective modulators of bradykinin B2 receptors | BDKRB2, BDKRB1, KISS1R | PKM 1141/4885NPSR1 116/4885CHRNB2 338/4885 |
| US-20020115693-A1 | Substituted imidazoles as selective modulators of bradykinin B2 receptors | BDKRB2, BDKRB1, KISS1R | PKM 1210/4885NPSR1 109/4885CHRNB2 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.